These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 30764072)

  • 21. Exenatide.
    Barnett AH
    Drugs Today (Barc); 2005 Sep; 41(9):563-78. PubMed ID: 16341288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stabilizing effect of exenatide in a patient with C-peptide-negative diabetes mellitus.
    Paisley AN; Savage MW; Wiles PG
    Diabet Med; 2009 Sep; 26(9):935-8. PubMed ID: 19719716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes.
    Fehse F; Trautmann M; Holst JJ; Halseth AE; Nanayakkara N; Nielsen LL; Fineman MS; Kim DD; Nauck MA
    J Clin Endocrinol Metab; 2005 Nov; 90(11):5991-7. PubMed ID: 16144950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy assessment of a GLP-1 mimetic: insulin glargine combination for treatment of feline diabetes mellitus.
    Scuderi MA; Ribeiro Petito M; Unniappan S; Waldner C; Mehain S; McMillian CJ; Snead EC
    Domest Anim Endocrinol; 2018 Oct; 65():80-89. PubMed ID: 30015124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.
    Triplitt C; Wright A; Chiquette E
    Pharmacotherapy; 2006 Mar; 26(3):360-74. PubMed ID: 16503716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exenatide Use in the Management of Type 2 Diabetes Mellitus.
    Kyriacou A; Ahmed AB
    Pharmaceuticals (Basel); 2010 Aug; 3(8):2554-2567. PubMed ID: 27713366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus.
    Bond A
    Proc (Bayl Univ Med Cent); 2006 Jul; 19(3):281-4. PubMed ID: 17252050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patients.
    Camastra S; Astiarraga B; Tura A; Frascerra S; Ciociaro D; Mari A; Gastaldelli A; Ferrannini E
    Diabetes Obes Metab; 2017 Mar; 19(3):412-420. PubMed ID: 27898183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exenatide: a new option for the treatment of type 2 diabetes.
    Yoo BK; Triller DM; Yoo DJ
    Ann Pharmacother; 2006 Oct; 40(10):1777-84. PubMed ID: 16985091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures.
    Mack CM; Moore CX; Jodka CM; Bhavsar S; Wilson JK; Hoyt JA; Roan JL; Vu C; Laugero KD; Parkes DG; Young AA
    Int J Obes (Lond); 2006 Sep; 30(9):1332-40. PubMed ID: 16534527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New drugs; exenatide and sitagliptin].
    van Bronswijk H; Dubois EA; Pijl H; Cohen AF
    Ned Tijdschr Geneeskd; 2008 Apr; 152(15):876-9. PubMed ID: 18512528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes.
    Nielsen LL; Okerson T; Holcombe J; Hoogwerf B
    J Diabetes Sci Technol; 2008 Mar; 2(2):255-60. PubMed ID: 19885351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
    Nauck MA; Meier JJ
    Regul Pept; 2005 Jun; 128(2):135-48. PubMed ID: 15780433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.
    Kolterman OG; Buse JB; Fineman MS; Gaines E; Heintz S; Bicsak TA; Taylor K; Kim D; Aisporna M; Wang Y; Baron AD
    J Clin Endocrinol Metab; 2003 Jul; 88(7):3082-9. PubMed ID: 12843147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
    Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes.
    Taylor K; Kim D; Nielsen LL; Aisporna M; Baron AD; Fineman MS
    Horm Metab Res; 2005 Oct; 37(10):627-32. PubMed ID: 16278786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes.
    Molina Vega M; Muñoz-Garach A; Tinahones FJ
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):207-217. PubMed ID: 29260924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exenatide treatment causes suppression of serum fasting ghrelin levels in patients with type 2 diabetes mellitus.
    Guclu M; Kiyici S; Gul Z; Cavun S
    Endocr Connect; 2018 Jan; 7(1):193-198. PubMed ID: 29217653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.